Vivek Subbiah: Indianapolis Rare Disease Symposium

Vivek Subbiah shared on X:

“Exhilarating discussions on how to move to needle in Rare Cancers in the era of personalized medicine & Precision Oncology at Indianapolis Rare Disease Symposium, Razelle Kurzrock, Ruemu Birhiray, Sumeet Bhatia!”

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.